Volpara to Showcase AI Software for Breast Centers at NCBC 2024, Including Lunit INSIGHT for Early Detection
Volpara to Showcase AI Software for Breast Centers at NCBC 2024, Including Lunit INSIGHT for Early Detection
Volpara's online customer community reaches 1,000-member milestone
Volpara 的在線客戶社區達到 1,000 名成員的里程碑
LYNNWOOD, Wash., March 15, 2024 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, will showcase its latest software advancements for breast centers at the 2024 National Consortium of Breast Centers (NCBC) conference, March 15-19 in Las Vegas. Volpara will feature Lunit's INSIGHT AI-software for early cancer detection alongside the company's suite of solutions for assessing breast density, evaluating cancer risk, and mammography quality.
華盛頓州林伍德，2024年3月15日 /PRNewswire/ — 癌症早期發現和預防軟件領域的全球領導者沃爾帕拉健康技術有限公司（澳大利亞證券交易所股票代碼：VHT）將在3月15日至19日在拉斯維加斯舉行的2024年全國乳腺中心聯盟（NCBC）會議上展示其乳腺中心的最新軟件進展。Volpara將採用Lunit的INSIGHT AI軟件進行早期癌症檢測，以及該公司用於評估乳房密度、評估癌症風險和乳房X光檢查質量的一套解決方案。
"NCBC comes at a time of great change for breast centers with new standards from the National Accreditation Program for Breast Centers (NAPBC), a national density inform mandate, and growing clinical demands combined with staff shortages," says Teri Thomas, Volpara CEO. "Success in this new era will require programs to embrace AI-powered solutions to automate, optimize and personalize care for providers and patients to thrive. Finding an AI partner you can trust has never been more important."
Volpara首席執行官泰瑞·托馬斯說：“NCBC是在乳腺中心國家認證計劃（NAPBC）的新標準、全國密度信息要求以及不斷增長的臨床需求以及人員短缺的情況下召開的。”“在這個新時代取得成功將需要項目採用人工智能驅動的解決方案，以自動化、優化和個性化護理，讓提供者和患者蓬勃發展。尋找值得信賴的人工智能合作伙伴從未如此重要。”
Volpara and Lunit join forces
Volpara previously announced it entered into a Scheme Implementation Agreement with Lunit. If the scheme is approved by Volpara shareholders and ultimately implemented, it is expected to be complete in Q2 2024. Regardless of the outcome of the scheme, a distribution agreement allows Volpara to sell Lunit's products immediately and offer a comprehensive suite that uses AI to enhance the mammography journey from screening to diagnosis.
Volpara 和 Lunit 聯手
Volpara此前曾宣佈與Lunit簽訂了計劃實施協議。如果該計劃獲得沃爾帕拉股東的批准並最終實施，則預計將在2024年第二季度完成。無論該計劃的結果如何，分銷協議都允許Volpara立即銷售Lunit的產品，並提供一套全面的套件，該套件使用人工智能來改善從篩查到診斷的乳房X光檢查過程。
Thriving Volpara customer community
Members of Volpara's Hive, the exclusive digital community for Volpara Health customers, will also gather at NCBC to discuss the latest AI research for breast centers. The Hive recently surpassed 1,000 members from diverse healthcare systems, imaging groups and breast centers, who connect online with peers and Volpara experts to knowledge share, access resources and spread best practices.
蓬勃發展 Volpara 客戶社區
Volpara旗下的Hive是Volpara Health客戶的專屬數字社區，其成員也將聚集在NCBC，討論乳房中心的最新人工智能研究。Hive最近有來自不同醫療系統、影像小組和乳房中心的1,000多名成員，他們在線與同行和Volpara專家建立聯繫，分享知識、獲取資源和傳播最佳實踐。
Singing River addresses health disparities with Volpara
Tami Hudson, RN, BSN, BHCN, CGRA, Breast Health Navigator, at Singing River Health System will present during the NCBC Clinical Post-Conference: Complexities of High-Risk Breast Care on Tuesday, March 19.
Singing River 使用 Volpara 解決健康差異
Singing River Health System的註冊護士、BSN、BHCN、CGRA、Breast Health Navigator的塔米·哈德森將於3月19日星期二出席NCBC臨床會後會議：高風險乳房護理的複雜性。
Hudson's presentation will review the clinical impact of making cancer risk assessment standard for every patient receiving a mammogram at four breast centers. The health system is located in a state that often ranks low in health outcomes and health literacy.
哈德森的演講將回顧爲在四個乳房中心接受乳房X光檢查的每位患者制定癌症風險評估標準所產生的臨床影響。衛生系統所處的州在健康結果和健康知識水平方面往往排名較低。
Singing River Health System has used Volpara Risk Pathways cancer risk assessment software to identify patients at elevated risk who are eligible for breast MRI or genetic testing over the past three years.
在過去三年中，Singing River Health System使用Volpara Risk Pathways癌症風險評估軟件來識別有資格接受乳房磁共振成像或基因檢測的高風險患者。
"Our comprehensive approach to care involves early identification and tailored support for high-risk patients. Genetic testing is a key tool for us," said Hudson. "Volpara Risk Pathways streamlines the overall process, helping patients receive the care they need for cancer prevention."
“我們的綜合護理方法包括早期識別和爲高危患者提供量身定製的支持。基因檢測是我們的關鍵工具，” 哈德森說。“Volpara風險路徑簡化了整個流程，幫助患者獲得癌症預防所需的護理。”
To see the latest software advancements for breast centers from Volpara visit Booth #303 at NCBC 2024.
要了解沃爾帕拉在乳房中心方面的最新軟件進展，請訪問NCBC 2024的 #303 號展位。
About Volpara Health (ASX: VHT)
關於 Volpara Health (ASX: VHT)
Volpara Health makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.
Volpara Health開發的軟件可以使家庭免受癌症的侵害。醫療保健提供者使用Volpara來更好地了解癌症風險，幫助患者做出個人護理決策，並指導有關其他成像、基因檢測和其他干預措施的建議。我們基於人工智能的圖像分析使放射科醫生能夠精確地量化乳腺組織，並幫助技術人員製作具有最佳圖像質量、定位、壓縮和劑量的乳房 X 光照片。在人員短缺日益嚴重的行業中，我們的軟件可以簡化運營並提供關鍵績效見解，以支持持續的質量改進。
Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,600 technologists, impacting nearly 17 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, the Company has raised A$132 million. With an office in Seattle, Volpara is based in Wellington, New Zealand.
Volpara是全球領先醫療機構的首選合作伙伴。超過5,600名技術人員在2,000多個設施中使用我們的軟件，影響了全球近1700萬名患者。它每年幫助提供者進行超過三百萬次癌症風險評估，可以獨立部署，也可以與電子健康記錄系統、乳房X光檢查報告系統、成像硬件和遺傳實驗室完全集成。Volpara 擁有最嚴格的安全認證和衆多專利和監管註冊，包括 FDA 許可和 CE 標誌。自2016年4月在澳大利亞證券交易所上市以來，該公司已籌集了1.32億澳元。Volpara在西雅圖設有辦事處，總部設在新西蘭惠靈頓。
For more information, visit .
欲了解更多信息，請訪問。
SOURCE Volpara Health, Inc.
來源 Volpara Health, Inc.
譯文內容由第三人軟體翻譯。